🚀 VC round data is live in beta, check it out!
2seventy bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for 2seventy bio and similar public comparables like Emergent BioSolutions, Eton Pharmaceuticals, AngioDynamics, Medios and more.
2seventy bio Overview
About 2seventy bio
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Founded
2021
HQ
Employees
65
Website
Financials (FY)
EV
$403M
2seventy bio Financials
2seventy bio reported last fiscal year revenue of $38M and negative EBITDA of ($98M).
In the same fiscal year, 2seventy bio generated $15M in gross profit, ($98M) in EBITDA losses, and had net loss of ($57M).
Revenue (LTM)
2seventy bio P&L
In the most recent fiscal year, 2seventy bio reported revenue of $38M and EBITDA of ($98M).
2seventy bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $38M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $15M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($98M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (260%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (279%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($57M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (151%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
2seventy bio Stock Performance
2seventy bio has current market cap of $472M, and enterprise value of $403M.
Market Cap Evolution
2seventy bio's stock price is $9.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $403M | $472M | -1.1% | XXX | XXX | XXX | $-1.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial2seventy bio Valuation Multiples
2seventy bio trades at 10.6x EV/Revenue multiple, and (4.1x) EV/EBITDA.
EV / Revenue (LTM)
2seventy bio Financial Valuation Multiples
As of March 29, 2026, 2seventy bio has market cap of $472M and EV of $403M.
Equity research analysts estimate 2seventy bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
2seventy bio has a P/E ratio of (8.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $472M | XXX | $472M | XXX | XXX | XXX |
| EV (current) | $403M | XXX | $403M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 26.3x | XXX | XXX | XXX |
| P/E | — | XXX | (8.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 2seventy bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
2seventy bio Margins & Growth Rates
2seventy bio's revenue in the last fiscal year declined by (62%).
2seventy bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (62%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (260%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (52%) | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 203% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
2seventy bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Eton Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| AngioDynamics | XXX | XXX | XXX | XXX | XXX | XXX |
| Medios | XXX | XXX | XXX | XXX | XXX | XXX |
| Regenxbio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
2seventy bio M&A Activity
2seventy bio acquired XXX companies to date.
Last acquisition by 2seventy bio was on XXXXXXXX, XXXXX. 2seventy bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by 2seventy bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free Trial2seventy bio Investment Activity
2seventy bio invested in XXX companies to date.
2seventy bio made its latest investment on XXXXXXXX, XXXXX. 2seventy bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by 2seventy bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 2seventy bio
| When was 2seventy bio founded? | 2seventy bio was founded in 2021. |
| Where is 2seventy bio headquartered? | 2seventy bio is headquartered in United States. |
| How many employees does 2seventy bio have? | As of today, 2seventy bio has over 65 employees. |
| Is 2seventy bio publicly listed? | Yes, 2seventy bio is a public company listed on Bolsa Mexicana de Valores. |
| What is the stock symbol of 2seventy bio? | 2seventy bio trades under TSVT ticker. |
| When did 2seventy bio go public? | 2seventy bio went public in 2021. |
| Who are competitors of 2seventy bio? | 2seventy bio main competitors are Emergent BioSolutions, Eton Pharmaceuticals, AngioDynamics, Medios. |
| What is the current market cap of 2seventy bio? | 2seventy bio's current market cap is $472M. |
| What is the current revenue of 2seventy bio? | 2seventy bio's last fiscal year revenue is $38M. |
| What is the current EV/Revenue multiple of 2seventy bio? | Current revenue multiple of 2seventy bio is 10.6x. |
| Is 2seventy bio profitable? | No, 2seventy bio is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.